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Abstract
Background: New biomarkers may aid in preventive and end-of-life decisions in older adults if they enhance the
prognostic ability of traditional risk factors. We investigated whether C-reactive protein (CRP) and/or B-type
natriuretic peptide (BNP) improve the ability to predict overall mortality among the elderly of the Bambuí, Brazil Study
of Aging when added to traditional risk factors.
Methods: From 1997 to 2007, 1,470 community-dwelling individuals (≥60 years) were followed-up. Death was
ascertained by continuous verification of death certificates. We calculated hazard ratios per 1 standard deviation
change (HR) of death for traditional risk factors only (old model), and traditional risk factors plus CRP and/or BNP
(new models) and assessed calibration of the models. Subsequently, we compared c-statistic of each of the new
models to the old one, and calculated integrated discriminative improvement (IDI) and net reclassification
improvement (NRI).
Results: 544 (37.0%) participants died in a mean follow-up time of 9.0 years. CRP (HR 1.28, 95% CI 1.17-1.40),
BNP (HR 1.31 95% CI 1.19-1.45), and CRP plus BNP (HR 1.26, 95% CI 1.15-1.38, and HR 1.29, 95% CI 1.16-1.42,
respectively) were independent determinants of mortality. All models were well-calibrated. Discrimination was similar
among the old (c-statistic 0.78 [0.78-0.81]) and new models (p=0.43 for CRP; p=0.57 for BNP; and p=0.31 for CRP
plus BNP). Compared to the old model, CRP, BNP, and CRP plus BNP models led to an IDI of 0.009 (p<0.001),
-0.005 (p<0.001) and -0.003 (p=0.84), and a NRI of 0.04 (p=0.24), 0.07 (p=0.08) and 0.06 (p=0.10), respectively.
Conclusions: Despite being independent predictors of long-term risk of death, compared to traditional risk factors
CRP and/or BNP led to either a modest or non-significant improvement in the ability of predicting all-cause mortality
in older adults.
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Introduction
Assessing the risk of mortality by clinical prediction scores is
particularly interesting in the elderly, as they may aid in
critically planning and carrying out preventive and end-of-life
quality interventions in individuals aged ≥60 years who
comprised approximately 51% of deaths worldwide [1] and
59% of total deaths in Brazil [2]. However, it has been
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described that traditional risk factors tend to lose their
predictive ability in this age group [3]. This leads to a special
interest in the use of biomarkers, such as C-reactive protein
(CRP) and B-type natriuretic peptide (BNP) in older adults.
CRP is a non-specific acute phase protein which is produced
predominantly by hepatocytes under the influence of cytokines,
such as interleukin (IL)-6 and tumor necrosis factor (TNF)-
alpha. High sensitive (hs)-CRP has been recognized as an
independent determinant of cardiovascular diseases and death
in the elderly [4,5]. Additionally, it allows the recognition of a
low-grade inflammatory state, which underlies both the ageing
process and several conditions closely associated with ageing,
such as atherosclerosis, Alzheimer’s disease, Parkinson’s
disease, type 2 diabetes mellitus, sarcopenia, osteoporosis,
cognitive decline, and frailty [4].
BNP, a 32-member of the family of the natriuretic peptides
(NPs), is mainly secreted by ventricular cardiomyocytes, and
promotes natriuresis, diuresis, vasodilatation and inhibition of
the renin-angiotensin-aldosterone system [6]. Besides the
hemodynamic actions, NP have anti-inflammatory, anti-fibrotic,
anti-proliferative and metabolic effects [7]. Clinically, NPs have
been used in the diagnosis of patients with acute dyspnea, as
well as prognostic tools in conditions, such as HF [8] and acute
coronary syndrome (ACS) [9]. In populations of community-
dwelling elderly, NPs were independent predictors of
cardiovascular events [10,11], hospitalization [12] and death
regardless of previous history of cardiovascular disorders
[10,11,13].
We investigated the additional value of CRP and/or BNP to
traditional risk factors in the prediction of 11-year all-cause
mortality risk in the population of elderly of the Bambuí, Brazil
Cohort Study of Aging (BHAS).
Methods
Ethics Statement
All participants signed an informed consent form and
authorized death certificate verification. The BHAS was
approved by the ethics board of the Fundação Oswaldo Cruz,
Belo Horizonte, Brazil.
Study design and population
The study was conducted in the Bambuí City (approximately
15,000 inhabitants), located in the state of Minas Gerais,
southeast region of Brazil. Procedures used in the BHAS have
been described in detail elsewhere [14]. Briefly, the baseline
cohort population comprised 1,606 (92.2%) of all residents
(1,742) aged 60 years or more on January 1st, 1997, who were
identified by means of a complete census. Baseline data
collection (standardized interviews, blood tests, blood pressure
measurements, and electrocardiograms) was performed from
February to May 1997.
Outcome Ascertainment
Deaths assigned to any cause and reported by next of kin
during the annual follow-up interview and ascertained through
the Brazilian Mortality Information System (Sistema de
Informações sobre Mortalidade) with the permission of the
Ministry of Health from study enrolment to December 31st, 2007
were included in this analysis. Death certificates were obtained
for 98.9% of all deceased participants.
CRP
Data on hs-CRP was available in 1,470 (91.5%) participants.
Blood samples were collected after 12-hours fast and serum
samples were stored at -80°C. Measurements were taken by
the CRP immunonephelometric method, Dade-Behring N Latex
CRP particle-enhanced immunoassay on an automatic
nephelometer (BNII™,Dade Behring, Marburg, Germany)
traceable to the international reference standard CRM 470 [15].
The limit of detection of the CRP assay as provided by the
manufacturer is 0.175-500mg/L and the CV is 2.2-5.8%.
Although very high (≥10mg/L) hs-CRP values are likely to be
due to systemic inflammatory states such as major infection,
trauma, or chronic inflammatory disease, we decided not to
exclude them as they might also be related to cardiovascular
risk and/or death [16].
BNP
BNP was measured in blood samples collected in tubes
containing ethylenediaminetetraacetic acid and stored at -80°C
until used. Subjects were asked to fast for 12 hours prior to
early-morning (6:30–8:30 AM) phlebotomy. A microparticle-
based immunoassay (MEIA/AxSYM; Abbott Laboratories) with
15-5,000 pg/mL as limits of detection and average interassay
coefficients of variation of 12% was used.
Traditional risk factors
The choice of the traditional risk factors to enter the models
was based on results of population studies about the risk of
death associated with non-communicable diseases, as well as
in previous investigations in the BHAS [17,18,19,20,21].
Current smoking was ascertained by the standardized BHAS
questionnaire. Systolic blood pressure was defined as the
mean of two lowest out of three standardized measurements.
Fasting blood glucose, total cholesterol (TC) and HDL were
determined using an automated analyser (Eclipse Vitalab,
Merck, The Netherlands). Diabetes was defined as a 12-h-fast
glucose ≥126 mg/dL and/or the use of insulin or oral
hypoglycemic agents. Two high-precision digital scales (range
0–150 kg×0.1 kg) were used for the measurement of weight
(kg) and height (cm). BMI was calculated as weight (kg)/ height
(m)2. Waist circumference (WC; cm) was measured at
umbilicus height by inelastic tapes. Leisure physical activity
was verified by standardized interview and defined as walking
and/or practicing any other physical exercise for at least 3-5
days/week, 20-30 min/day within the last 90 days. Chagas
disease was also investigated as a traditional risk factor
because it used to be endemic in the region of Bambuí city until
the 1970s. Following the control by insecticides, the incidence
of the infection with Trypanossoma cruzi has dramatically
decreased, but a cohort effect led to a high prevalence (38.1%)
of chronic Chagas disease in the elderly [22]. Diagnosis relies
on serologic methods and was defined by seropositivity in all
three of the different parallel tests: a hemagglutination assay
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(Biolab Mérieux SA, Rio de Janeiro, Brazil) and 2 enzyme-
linked immunosorbent assays (Abbott Laboratories, Inc., North
Chicago, Illinois; and Wiener Laboratories, Rosario, Argentina).
The absence of infection was defined as consistent
seronegativity. The agreement (Cohen’s kappa) among these
assays was 0.989 (p < 0.001).
Statistical analysis
Normal distribution of continuous data was verified by
histograms and Komolgorov-Smirnov tests. Variables with a
skewed distribution were log-transformed (BNP, CRP).
Continuous variables were described by mean and standard
deviation (SD), or median and inter-quartile range (IQR). To
compare baseline characteristics across BNP and CRP tertiles
we used the Chi-square test for linear trends, the ANOVA with
post hoc Bonferroni correction for continuous variables with
normal distribution (age, systolic blood pressure, total
cholesterol, HDL, and WC) and the Mann-Whitney tests. We
compared survival rates across the tertiles of CRP (<1.88,
1.88-5.18, ≥5.18 mg/L) and BNP (<55, 55-119, ≥119 pg/mL) by
means of Kaplan Meier curves and log-rank tests. To deal with
missing values, we performed multiple imputation by fitting
logistic and linear regression models with both the predictors
and the outcome, as well as other variables regarded as
important to explain the missing values [23]. This procedure
generated five complete datasets, which were used to estimate
crude and adjusted hazard ratios (HR) and 95% confidence
intervals (CI) for death by Cox regression models. Proportional
hazards assumption was verified by plotting the log of the
cumulative hazard against the log of follow-up time. The first
model (old model) was fitted for traditional risk factors only: age
(continuous), gender, current smoking (no, yes), systolic blood
pressure (continuous), total cholesterol (continuous), HDL
(continuous), BMI (continuous and squared), WC (continuous),
physical activity (no, yes), and Chagas disease (no, yes). For
the other three models (new models), we additionally adjusted
for log-transformed CRP (continuous) and log-transformed
BNP (continuous) individually and simultaneously. As Chagas
disease is a prevalent comorbidity in our population, we tested
for the effect modification of Chagas on the association
between each of the biomarkers and death by means of
product terms of interaction. We also performed sensitivity
analysis with complete original data.
To aid in clinical decision-making in the context of the
rational use of resources, a biomarker must be both an
independent determinant of the outcome and incrementally
improve the predictive ability of models that are based on
established risk factors only [16]. Thus, we also assessed the
performance of the models by calibration and discrimination.
For assessment of calibration, i.e. agreement between
observed and predicted events, we used a modified Hosmer-
Lemeshow chi-square statistic. Observed incidence of the
outcome was obtained by the Kaplan-Meier estimator, which
was then compared to the probabilities of events predicted by
Cox models at the end of the follow-up (t=11), across ten
groups yielded by the deciles of the predicted probabilities [24].
For assessment of the ability of each survival model to
discriminate between individuals at different risk levels of
death, we used Harrell’s C statistics and compared the ROC
for each new model to the old one by means of the Hanley and
McNeill [25] [26]. Additionally, models with CRP and BNP
individually and in combination were each compared to the
model with traditional risk factors only by means of integrated
discrimination improvement (IDI) and retrospective category-
free net reclassification improvement (NRI). IDI refers to
differences in integrated sensitivity and integrated one minus
specificity between the new and the old models [27]. Category-
free NRI, according to Pencina et al., quantifies how the
addition of a new biomarker correctly increases (upwards
movements) or decreases (downwards movements) the risk
predicted by the model for events and non-events. NRI
calculations were based on the predicted probabilities of an
event derived from predicted probabilities at the end of the
follow-up (t=11) estimated by Cox regression models [28]. All
the p values given are two-sided with the level of significance
set to p<0.05, except for multiple comparisons when it was set
to 0.05 divided by the number of comparisons. We used SPSS
for Windows 17.0 and R 2.15.1 (package survivalROC).
Results
Mean age (SD) of the participants was 69.1 (7.2) years and
895 (61.0%) were female. Mean follow-up time was 9.0 years.
At 11-years of follow-up, 544 participants (37.0%) died and 89
(5.5%) were lost to follow-up, leading to 13,230 person-years of
observation. Subjects with complete follow-up had similar
median CRP (3.25 mg/L, IQR 1.45-6.70 versus 3.06 mg/L, IQR
1.26-5.73; p=0.38) and BNP values (82 pg/mL, IQR 44-148
versus 64 pg/mL, IQR 39-157; p=0.49) than those who were
lost to follow-up.
Characteristics
Among the traditional risk factors, BMI, diabetes, HDL and
total cholesterol were different across CRP categories, and
BMI and WC were different across the BNP categories (Table
1). All the traditional risk factors were independent
determinants of death at 10-year follow-up in the BHAS
population, except for HDL-cholesterol (Table 2).
Outcomes in relation to CRP and BNP
Univariate survival rates at 11-year follow-up across CRP
and BNP tertiles are depicted in Figures 1 and 2, respectively.
After adjustment for the traditional risk factors, CRP and BNP
remained independent predictors of death in the 11-year follow-
up in the models in which the biomarkers were added
individually (HR per 1 SD change 1.28, 95% CI 1.17-1.40, and
HR per 1 SD change 1.31 95% CI 1.19-1.45, respectively) and
simultaneously (HR per 1 SD change 1.26, 95% CI 1.15-1.38,
and HR 1.29 95% CI 1.16-1.42, respectively). Neither was the
interaction between BNP and Chagas (p=0.94), nor between
CRP and Chagas (p=0.24) significant in BHAS population.
These results did not change significantly from models with
only complete original data in which CRP and BNP individually
(HR per 1 SD change 1.24, 95% CI 1.12-1.36, and HR per 1
SD change 1.29 95% CI 1.17-1.43, respectively) and in
combination (HR per 1 SD change 1.21, 95% CI 1.10-1.34, and
CRP, BNP and Mortality in Older Adults
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HR per 1 SD change 1.27, 95% CI 1.15-1.41, respectively)
were associated with an increased risk of death.
Performance of the models
The deciles of observed rates of events were not significantly
different from those predicted by the model with traditional risk
factors only, which indicates that it was well-calibrated
(X2=1.21, p=1.00). Models with CRP (X2=1.14, p=1.00) and
BNP individually (X2=1.33, p=1.00) or in combination (X2=1.52,
p=1.00) were also well-calibrated.
Harrell’s C-statistic for the model with traditional risk factors
only was 0.78 (95% CI 0.77-0.81) and did not differ significantly
from the model with CRP 0.79 (95% CI 0.77-0.81; p=0.43),
BNP 0.79 (95% CI 0.76-0.81; p=0.57), and CRP and BNP
simultaneously 0.79 (95% CI 0.78-0.82; p=0.31).
IDI was modest for the addition of CRP (IDI=0.009;
p=<0.001), BNP (IDI=-0.005; p=<0.001) and both of the
biomarkes (IDI=-0.003; p=0.84) to the model with traditional
risk factors only. Moreover, the addition of CRP led to small
non-significant changes in the prediction of death (NRI=0.04;
95% CI -0.02 to 0.09; p=0.24) by the model. Changes in the
risk of death estimated by the model were also non-significant
when BNP was added to traditional risk factors (NRI=0.07; 95%
CI -0.01 to 0.14; p=0.08) and when BNP and CRP were
simultaneously added to the model (NRI=0.06; 95% CI -0.01 to
0.12; p=0.10) Figures 3-5 display the estimated risk of death for
both subjects who died and survived during the follow-up time
for each of the new models compared to the model based on
traditional risk factors only.
Discussion
In a population of community-dwelling elderly in Bambuí,
Brazil, CRP and BNP were determinants of long-term mortality
independently of traditional risk factors. However, although the
models with the biomarkers were well-calibrated, neither CRP
nor BNP individually or in combination led to a significant
improvement in the ability of the model in discriminating
different levels of risk of mortality. Furthermore, the addition of
the biomarkers led to at most small correct changes in the
estimation of the risk of mortality. This suggests that, although
there is a clinical demand to predict death in the elderly to aid
in decisions regarding preventative and curative interventions
as well as palliative care, the incremental value of CRP and/or
BNP compared to more established risk factors is probably too
modest.
Biological explanations
CRP and BNP are components of different biological
pathways that may lead to death. The positive association
between CRP and increased mortality in the elderly may be
directly associated with the physiological immune response
Table 1. Characteristics of overall participants at baseline, and comparison according to the tertiles of C-reactive protein and
B-type natriuretic peptides.
Characteristics Overall CRP category p value* BNP category p value*
  Low Intermediate High  Low Intermediate High  
  (<1.88 mg/L) (1.88-5.18mg/L) (≥ 5.18mg/L)  (<55 pg/mL) (55-119pg/mL) (≥ 119pg/mL)  
Age, years 69 (7.4) 69 (7.0) 68 (7.0) 69 (7.0) 0.033 68 (6.6) 69 (7.1) 70 (7.7) <0.001
Female sex (%) 964 (60.0) 264 (53.9) 313 (63.9) 318 (64.9) <0.001 280 (57.6) 300 (60.6) 315 (63.9) 0.044
Smoking (%) 264 (16.4) 77 (16.0) 94 (19.5) 90 (18.9) 0.243 92 (19.3) 88 (18.1) 82 (17.1) 0.385
BMI (Kg/m2) 24.8 (21.7-27.9) 23.3 (20.8-26.4) 25.1 (22.7-26.1) 28.0 (22.4-29.3) <0.001 25.8 (22.8-28.9) 24.3 (21.4-27.6) 24.0 (21.0-27.3) <0.001
WC (cm) 91 (11.2) 88 (10.3) 91 (10.6) 94 (11.9) <0.001 93 (11.4) 90 (10.9) 90 (10.9) <0.001
Chagas disease (%) 557 (34.7) 180 (37.5) 190 (39.4) 176 (37.1) 0.889 105 (22.0) 167 (34.4) 274 (57.2) <0.001
SBP (mm Hg) 137 (22.6) 135 (21.0) 139 (21.0) 138 (25.0) 0.060 137 (19.5) 136 (23.1) 139 (24.2) 0.072
Diabetes (%) 209 (13.0) 52 (10.8) 58 (12.1) 90 (19.0) <0.001 73 (13.6) 66 (13.2) 63 (19.0) 0.351
Total cholesterol (mg/dL) 234 (49.1) 229 (48.0) 238 (48.0) 234 (51.0) 0.024 239 (51.4) 232 (47.2) 231 (48.3) 0.031
HDL (mg/dL) 49 (15) 50 (41-60) 46 (38-55) 45 (38-55) <0.001 49 (14.9) 50 (15.6) 49 (14.6) 0.238
Anti-hypertensive
medication (%) 742 (46.2) 200 (41.7) 251 (52.1) 279 (58.7) <0.001 234 (49.1) 246 (50.7) 251 (52.4) 0.301
Physically active (%)† 329 (20.5) 106 (21.6) 106 (21.7) 99 (20.2) 0.584 129 (26.6) 92 (18.6) 92 (18.7) 0.002
CRP C-reactive protein; BNP B-type natriuretic peptide; BMI body mass index; SBP systolic blood pressure; WC waist circumference
Data based on the complete original dataset with the following number of participants with available observations for each covariate: CRP (n=1470), BNP (n=1474),Age
(n=1606), sex (n=1606), smoking (n=1462), BMI (n=1450), WC (n=1454), Chagas (n=1462), systolic blood pressure (n=1459), diabetes (n=1458), total cholesterol (n=1461),
HDL (n=1461), anti-hypertensive medication (n=1462), physical activity (n=1605). Frequencies (%), mean (standard deviation) and median (interquartile range) are
displayed for categorical (female sex, smoking, Chagas disease, diabetes, anti-hypertensive medication and physically active) and continuous variables with normal (age,
WC, SBP, total cholesterol, HDL) and skewed distribution (BMI) respectively
*p Value: ANOVA test with Bonferroni correction, Pearson’s chi-square test for linear trends and the Kruskal Wallis test for differences between means, frequencies and
medians, respectively
† Leisure physical activity (walking or any other physical exercise) for at least 20-30min, ≥3-5 times/week
doi: 10.1371/journal.pone.0075809.t001
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associated with the ageing process [29] or be mediated by a
broad range of inflammatory and thrombotic conditions, such
as atherosclerosis [30] and cardiovascular diseases [31,32]. As
well, augmented hs-CRP levels are associated with an
increased risk of decreased muscle function [33], disability and
functional decline [34], osteoporotic and non-traumatic
fractures [35,36], visceral adiposity [37], and hospitalization
[38].
Several biological mechanisms are implicated in the
association between high BNP levels and death in the elderly.
Systolic and diastolic dysfunction can lead to an increase in
plasmatic BNP levels. Myocardial fibrosis, ventricular
hyperthophy, preclinical and symptomatic myocardial ischemia,
and renal dysfunction, which are associated with an increased
Table 2. Crude and adjusted hazard ratios (HR) per
standard deviation change and 95% confidence interval (CI)
of death in the model with traditional risk factors only.
Variable Crude HR (95% CI)
HR adjusted for other
traditional risk factors
*(95% CI)
 
Imputation
dataset
Complete
dataset
Imputation
dataset
Complete
dataset
Age (years) 1.90(1.89-1.92)
1.90
(1.89-1.92)
1.83
(1.68-2.00)
1.84
(1.82-1.85)
Male sex 1.45(1.22-1.73)
1.45
(1.22-1.73)
1.34
(1.10-1.63)
1.35
(1.10-1.66)
Total cholesterol
(mg/dL)
0.86
(0.78-0.95)
0.86
(0.78-0.95)
0.86
(0.78-0.95)
0.86
(0.78-0.95)
HDL-cholesterol
(mg/dL)
1.06
(0.97-1.16)
1.06
(0.97-1.16)
1.00
(0.92-1.09)
1.00
(0.92-1.09)
Diabetes † 1.34(1.06-1.70)
1.35
(1.06-1.70)
1.54
(1.20-1.98)
1.63
(1.26-2.11)
Smoking † 1.66(1.36-2.04)
1.67
(1.36-2.04)
1.54
(1.23-1.92)
1.55
(1.23-1.96)
Systolic blood
pressure (mm
Hg)
1.23
(1.12-1.34)
1.23
(1.12-1.34)
1.17
(1.07-1.28)
1.17
(1.07-1.28)
Physical activity
†
0.57
(0.44-0.73)
0.57
(0.44-0.73)
0.63
(0.49-0.81)
0.65
(0.50-0.84)
Body mass index
(kg/m2)
0.71
(0.64-0.79)
0.73
(0.65-0.81)
0.20
(0.12-0.34)
0.20
(0.12-0.34)
Waist
circumference
(cm)
0.85
(0.85-0.86)
0.87
(0.80-0.95)
1.27
(1.06-1.51)
1.27
(0.22-7.33)
Chagas disease
†
1.47
(1.23-1.76)
1.47
(1.23-1.76)
1.45
(1.21-1.75)
1.48
(1.22-1.79)
* Model adjusted for: age (continuous), gender, body mass index (continuous and
quadratic term), waist circumference (continuous), diabetes (no, yes), systolic
blood pressure (no, yes), total cholesterol (continuous), HDL-cholesterol
(continuous), current smoking (no, yes), physical activity (no, yes), Chagas disease
(no, yes)
† The following categories were used as references (HR=1) for the categorical
covariates: non-diabetic, non-smokers, sedentary, and non-infected by Chagas
disease subjects
doi: 10.1371/journal.pone.0075809.t002
risk of death in the elderly, lead to elevated BNP levels [39].
Moreover, due to still poorly defined mechanisms, high BNP
levels are associated with a higher incidence of stroke [40], as
well as with poor functional outcomes [41]. In our population,
Chagas disease, which is independently associated with high
BNP levels [42], is an additional factor to explain the increased
risk of death related to elevated BNP levels.
Comparison with other studies
Previous studies that investigated the issue of the value of
hs-CRP in predicting cause-specific, mostly cardiovascular,
and/or overall mortality in community-dwelling elderly yielded
heterogeneous results. Neither was hs-CRP independently
related to overall mortality in an older adult population without
heart or renal failure followed-up for five years [39] nor in
women aged at least 65 years old [43]. Moreover, it did not
predict the combined end-point of major CV events and CV
death in a population of older adults followed-up for
approximately 10 years [44]. On the other hand, similarly to our
findings, CRP was an independent determinant of 4-year all-
cause mortality both in community-dwelling populations of frail
[4] and non-disabled [5] elderly.
Regarding the association between natriuretic peptides and
mortality, our results point to an independent prognostic value
of BNP, in agreement with other population-based studies
which investigated the role of different NPs as determinants of
overall and cause-specific death in older adults [10] [45] [46],
including a previous investigation in the elderly with Chagas
disease in the BHAS [47]. However, none of these studies with
CRP or BNP performed measures of the incremental value of
the biomarker in predicting overall mortality.
Regarding the association of CRP and BNP as prognostic
markers, an investigation of the Framingham Offspring Study
which compared C-statistic between models with traditional risk
factors only and with the addition of a multi-marker score that
included both hs-CRP and BNP found that only BNP led to a to
a small increase in the ability of the model in discriminating
between death and survival in older adults [48]. On the other
hand, CRP and NT-proBNP, a precursor of BNP, were
independently related to CV and overall mortality and a score
formed by the two biomarkers plus three others substantially
improved the predictive ability over conventional risk factors in
a population of older adults with mean age of 71 years [49].
Strengths and limitations
Comparing different aspects of the models predictive
performance by NRI and IDI, and not only by hazard ratios and
discrimination, which have been shown to have important
pitfalls [50], strengthen the results of the present investigation.
The long-term follow-up, the minimal lost to follow-up, and
adjustment for a large set of potential confounders on the
association between the biomarkers and death are other major
strengths of our study. Particularly, adjustment for WC, which is
a surrogate of visceral adiposity, can be important, as previous
studies observed that the age-associated variation in CRP is
related to the amount of visceral adipose tissue [37], and that
visceral adiposity predicts death. We believe that these results
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can be generalized to other Brazilian populations with a high
prevalence of cardiovascular diseases.
However, several limitations must be acknowledged. We
only had a single baseline measurement of each of the
biomarkers. Regarding hs-CRP, an extra measurement can be
advisable due to fluctuations in systemic inflammatory status
over time [16]. We were not able to investigate the influence of
medications, such as statins, anti-inflammatory and anti-
diabetic drugs, on hs-CRP levels. Whether the prognostic value
Figure 1.  Survival rates up to 11-year follow-up for the tertiles of C-reactive protein (CRP).  
doi: 10.1371/journal.pone.0075809.g001
Figure 2.  Survival rates up to 11-year follow-up for the tertiles of B-type natriuretic peptide (BNP).  
doi: 10.1371/journal.pone.0075809.g002
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of the biomarkers differs between cause-specific and overall
mortality was not addressed in the present study either.
In conclusion, CRP and BNP individually or combined are
independent determinants of death in this community-dwelling
elderly population. However, the incremental value of these
biomarkers to traditional risk factors seems to be either small or
non-significant. These findings point out that CRP and BNP
probably should not be used to aid in decisions about
prevention of overall mortality in the elderly. Further
investigation of cost-benefit issues is also necessary to better
understand the incremental value of these biomarkers.
Figure 3.  Estimated 11-year risk of mortality by the models with traditional risk factors only and after addition of CRP.  
doi: 10.1371/journal.pone.0075809.g003
Figure 4.  Estimated 11-year risk of mortality by the models with traditional risk factors only and after addition of BNP.  
doi: 10.1371/journal.pone.0075809.g004
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Figure 5.  Estimated 11-year risk of mortality by the models with traditional risk factors only and after addition of CRP
and BNP simultaneously.  
doi: 10.1371/journal.pone.0075809.g005
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